danicamtiv + diltiazem

Danicamtiv + diltiazem is an experimental combination of two small molecule drugs currently in clinical trials. Danicamtiv is a novel, selective cardiac myosin activator designed to enhance cardiac contractility by directly activating cardiac myosin, thereby improving systolic function in conditions such as heart failure with reduced ejection fraction (HFrEF) and primary dilated cardiomyopathy (DCM). Diltiazem is a well-established calcium channel blocker (specifically acting on the L-type calcium channel), used for managing hypertension, angina, and certain arrhythmias; in DCM, it can improve ventricular function and symptoms. The combination is being investigated primarily to study pharmacokinetics, pharmacodynamics, and drug-drug interactions, as diltiazem inhibits CYP3A4, which could potentially affect the metabolism of danicamtiv. This combination does not have an approved indication as a fixed product; it is studied to assess safety, efficacy, and interaction profiles in cardiovascular disease populations, mainly DCM and HFrEF[2][6][1].

Other names

danicamtivdiltiazem